Avalo Therapeutics (AVTX) Common Equity (2016 - 2025)
Historic Common Equity for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $91.5 million.
- Avalo Therapeutics' Common Equity rose 33436.61% to $91.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.5 million, marking a year-over-year increase of 33436.61%. This contributed to the annual value of $133.0 million for FY2024, which is 172135.82% up from last year.
- Avalo Therapeutics' Common Equity amounted to $91.5 million in Q3 2025, which was up 33436.61% from $104.6 million recorded in Q2 2025.
- Over the past 5 years, Avalo Therapeutics' Common Equity peaked at $133.0 million during Q4 2024, and registered a low of -$112.5 million during Q1 2024.
- For the 5-year period, Avalo Therapeutics' Common Equity averaged around $24.3 million, with its median value being $14.7 million (2023).
- Within the past 5 years, the most significant YoY rise in Avalo Therapeutics' Common Equity was 172135.82% (2024), while the steepest drop was 169578.75% (2024).
- Quarter analysis of 5 years shows Avalo Therapeutics' Common Equity stood at $23.1 million in 2021, then crashed by 147.29% to -$10.9 million in 2022, then skyrocketed by 166.92% to $7.3 million in 2023, then skyrocketed by 1721.36% to $133.0 million in 2024, then crashed by 31.18% to $91.5 million in 2025.
- Its Common Equity stands at $91.5 million for Q3 2025, versus $104.6 million for Q2 2025 and $122.6 million for Q1 2025.